Cost-effectiveness of digoxin versus beta blockers in permanent atrial fibrillation: the Rate Control Therapy Evaluation in Permanent Atrial Fibrillation (RATE-AF) randomised trial - Abdali, Zainab; Bunting, Karina V; Mehta, Samir; Camm, John; Rahimi, Kazem; Stanbury, Mary; Haynes, Sandra; Kotecha, Dipak; Jowett, Sue (Heart (British Cardiac Society), 2025)
Keywords: Adrenergic beta-Antagonists - administration & dosage; Adrenergic beta-Antagonists - adverse effects; Adrenergic beta-Antagonists - economics; Adrenergic beta-Antagonists - therapeutic use; Aged; Aged, 80 and over; Anti-Arrhythmia Agents - administration & dosage; Anti-Arrhythmia Agents - adverse effects; Anti-Arrhythmia Agents - economics; Anti-Arrhythmia Agents - therapeutic use; Atrial Fibrillation; Atrial Fibrillation - drug therapy; Atrial Fibrillation - economics; Atrial Fibrillation - physiopathology; Beta blockers; Cardiac arrhythmia; Cost analysis; Cost control; Cost-Benefit Analysis; Digoxin - administration & dosage; Digoxin - adverse effects; Digoxin - economics; Digoxin - therapeutic use; Drug Costs; Economic analysis; Female; Health care; Health Care Economics and Organizations; Health services; Healthcare Delivery, Economics and Global Health; Heart failure; Heart rate; Heart Rate - drug effects; Hospitals; Humans; Male; Original Research; Patient admissions; Primary care; Prospective Studies; Quality of Health Care; Quality of Life; Quality-Adjusted Life Years; Questionnaires; Treatment Outcome; United Kingdom; United Kingdom; United Kingdom--UK; Health Care Economics and Organizations; Atrial Fibrillation; Quality of Health Care